Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

While there have been massive strides forward in treating cancer in the last decades – with a doubling in survival rates in the last ... and an ongoing lung cancer screening drive rolled out ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...